New strategies for bone marrow transplantation

Current Opinion in Immunology

Volumn 12, Issue 5, 2000, Pages 542-551

  Slavin, Shimon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CHIMERA; CLINICAL PRACTICE; CLINICAL PROTOCOL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; TREATMENT INDICATION;

EID: 0033812626     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00136-9     Document Type: Review

References (65)

1. Antileukemic effect of chronic graft-versus-host disease: Contribution to improved survival after allogeneic marrow transplantation
2. Anti-leukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation
3. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia
4. Graft-versus-leukemia reactions after bone marrow transplantation
5. Effect of hematopoietic chimerism on the course of Rauscher's viral mouse leukemia
6. Time pattern of the anti-leukemia effect of graft-versus-host reaction in mice, I. Cellular events
7. Graft-versus-leukaemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity
8. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI)
9. Characterization of alloimmunization-induced T lymphocytes reactivated against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo
10. Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man
11. Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT)
12. Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes
13. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation
14. Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation
15. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy
16. T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse
17. Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies
18. Effective graft vs leukemia effects independent of graft vs host disease after T-cell depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and rIL-2
19. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions
20. T-cell depleted bone marrow transplantation and delayed T-cell add-back to control severe acute GVHD and conserve a GVL effect
21. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic BMT for beta thalassemia major
22. Conditioning regimen for optimal elimination of self-reactivity in association with autologous and allogeneic cell therapy in patients with severe autoimmune diseases
23. Long-term survival of skin allogafts in mice treated with fractionated total lymphoid irradiation
24. Total lymphoid irradiation (TLI)
25. Tolerance to donor-type skin in the recipient of a bone marrow allograft
26. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts
27. Mixed allogeneic chimeras prepared by a non-myeloablative regimen: Requirement for chimerism to maintain tolerance
28. Mixed allogeneic chimerism as an approach to transplantation tolerance
29. Anti-CD154 or CTLA4lg obviates the need for thymic irradiation in an non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance
30. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment
31. Permanent and specific transplantation tolerance induced by a non-myeloablative treatment to a wide variety of allogeneic tissues
32. Transplantation of allogeneic or xenogeneic bone marrow within the donor stromal microenvironment
33. Non-myeloablative conditioning to induce bilateral tolerance after allogeneic bone marrow transplantation in mice
34. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
35. Stem cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients
36. Prevention and treatment of graft-versus-host disease by down-regulation of anti-host reactivity with veto cells of host origin
37. A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients
38. Monoclonal antibodies for prevention of graft-versus-host disease and marrow graft rejection
39. Transplantation of anergic histoincompatible bone marrow allografts
40. Stable mixed hematopoietic chimerism in dog leukocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation
41. Stable mixed hematopoietic chimerism in dogs given donor antigen, CTLA4lg, and 100 cGy total body irradiation before and pharmacologic immunosuppression after marrow transplant
42. Graft vs autoimmunity (GVA) following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic arthritis
43. Engraftment of allogeneic hematopoietic progenitor cells with analog-containing chemotherapy: Harnessing-versus-leukemia without myeloablative therapy
44. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases
45. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
46. Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy
47. Mixed hematopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting
48. Mini-allografts: Ongoing trials in humans
49. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia
50. Well-tolerated non-myeloablative fludarabine-based protocols for the treatment of malignant and non-malignant disorders with allogeneic bone marrow or blood stem cell transplantation
51. Functional clonal deletion versus active suppression in transplantation tolerance induced by total lymphoid irradiation (TLI)
52. A new non-myeloablative protocol using fludarabine and low-dose TBI in preparation for allogeneic blood stem cell transplantation for high risk patients with malignant and non-malignant disorders
53. Hematopoietic stem cell transplants (HSCT) from HLA matched and mismatched unrelated donors using a non-myeloablative regimen
54. Treatment of high-risk acute leukemia with T-cell-depleted cells from related donors with one fully mismatched HLA
55. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB x NZW)F1 hybrids with spontaneous lymphosarcoma
56. Allogeneic cell therapy for a murine mammary carcinoma
57. Allogeneic cell therapy for a murine mammary carcinoma
58. Evidence for a graft-vs-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
59. Allogeneic cell mediated immunotherapy for breast cancer after autologous stem cell transplantation: A clinical pilot study
60. Graft vs tumor and graft vs leukemia in patient with concurrent breast cancer and acute myelocytic leukemia
61. Successful treatment of metastatic renal-cell carcinoma with a non-myeloablative allogeneic peripheral blood progenitor cell transplant: Evidence for a graft-versus tumor effect
62. Development of antibodies to hepatitis B virus surface antigen in bone marrow transplant recipients following treatment with peripheral blood lymphocytes from immunized donors
63. Human minor histocompatibility antigens: New concepts for marrow transplantation and adoptive immunotherapy
64. Feasibility of immunotherapy of relapsed leukemia with ex vivo generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens